Cargando…

Increased circulating adiponectin is an independent disease activity marker in patients with rheumatoid arthritis: A cross-sectional study using the KURAMA database

OBJECTIVE: To clarify the relationship among serum adiponectin, body composition, current disease activity and therapeutics of rheumatoid arthritis (RA). METHODS: We conducted a cross-sectional study in RA patients under treatment with agents including biological disease-modifying antirheumatic drug...

Descripción completa

Detalles Bibliográficos
Autores principales: Minamino, Hiroto, Katsushima, Masao, Yoshida, Tamami, Hashimoto, Motomu, Fujita, Yoshihito, Shirakashi, Mirei, Yamamoto, Wataru, Murakami, Kosaku, Murata, Koichi, Nishitani, Kohei, Tanaka, Masao, Ito, Hiromu, Inagaki, Nobuya, Matsuda, Shuichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7053773/
https://www.ncbi.nlm.nih.gov/pubmed/32126127
http://dx.doi.org/10.1371/journal.pone.0229998
_version_ 1783503104810942464
author Minamino, Hiroto
Katsushima, Masao
Yoshida, Tamami
Hashimoto, Motomu
Fujita, Yoshihito
Shirakashi, Mirei
Yamamoto, Wataru
Murakami, Kosaku
Murata, Koichi
Nishitani, Kohei
Tanaka, Masao
Ito, Hiromu
Inagaki, Nobuya
Matsuda, Shuichi
author_facet Minamino, Hiroto
Katsushima, Masao
Yoshida, Tamami
Hashimoto, Motomu
Fujita, Yoshihito
Shirakashi, Mirei
Yamamoto, Wataru
Murakami, Kosaku
Murata, Koichi
Nishitani, Kohei
Tanaka, Masao
Ito, Hiromu
Inagaki, Nobuya
Matsuda, Shuichi
author_sort Minamino, Hiroto
collection PubMed
description OBJECTIVE: To clarify the relationship among serum adiponectin, body composition, current disease activity and therapeutics of rheumatoid arthritis (RA). METHODS: We conducted a cross-sectional study in RA patients under treatment with agents including biological disease-modifying antirheumatic drugs (bDMARDs) and Janus kinase (JAK) inhibitors. A total of 351 subjects from the Kyoto University RA Management Alliance cohort (KURAMA) were enrolled in the analysis. We classified the participants into five body composition groups according to the cut-off points for obesity and visceral fat used in Japan: body mass index (BMI), 18.5 kg/m(2) for underweight and 25.0 kg/m(2) for obesity, and visceral fat area (VFA), 100 cm(2) for visceral adiposity. RESULTS: Classification of body composition revealed that serum adiponectin levels and disease activity score (DAS28-ESR) in the low BMI group were significantly higher than those in the normal and overweight groups. Because both increased serum adiponectin and low BMI were previously reported as poor prognostic factors of RA, we performed multiple regression analysis to determine which factor was correlated with RA disease activity. Serum adiponectin level, but not BMI, was positively associated with DAS28-ESR (estimate = 0.0127, p = 0.0258). Subanalysis also showed that the use of bDMARD or JAK inhibitor did not have an obvious influence on circulating adiponectin. CONCLUSIONS: Classification of body composition and multiple regression analysis revealed a positive and independent correlation between serum adiponectin and DAS28-ESR in Japanese RA patients. Thus, serum adiponectin may be an important marker reflecting high disease activity of RA regardless of current medications.
format Online
Article
Text
id pubmed-7053773
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-70537732020-03-12 Increased circulating adiponectin is an independent disease activity marker in patients with rheumatoid arthritis: A cross-sectional study using the KURAMA database Minamino, Hiroto Katsushima, Masao Yoshida, Tamami Hashimoto, Motomu Fujita, Yoshihito Shirakashi, Mirei Yamamoto, Wataru Murakami, Kosaku Murata, Koichi Nishitani, Kohei Tanaka, Masao Ito, Hiromu Inagaki, Nobuya Matsuda, Shuichi PLoS One Research Article OBJECTIVE: To clarify the relationship among serum adiponectin, body composition, current disease activity and therapeutics of rheumatoid arthritis (RA). METHODS: We conducted a cross-sectional study in RA patients under treatment with agents including biological disease-modifying antirheumatic drugs (bDMARDs) and Janus kinase (JAK) inhibitors. A total of 351 subjects from the Kyoto University RA Management Alliance cohort (KURAMA) were enrolled in the analysis. We classified the participants into five body composition groups according to the cut-off points for obesity and visceral fat used in Japan: body mass index (BMI), 18.5 kg/m(2) for underweight and 25.0 kg/m(2) for obesity, and visceral fat area (VFA), 100 cm(2) for visceral adiposity. RESULTS: Classification of body composition revealed that serum adiponectin levels and disease activity score (DAS28-ESR) in the low BMI group were significantly higher than those in the normal and overweight groups. Because both increased serum adiponectin and low BMI were previously reported as poor prognostic factors of RA, we performed multiple regression analysis to determine which factor was correlated with RA disease activity. Serum adiponectin level, but not BMI, was positively associated with DAS28-ESR (estimate = 0.0127, p = 0.0258). Subanalysis also showed that the use of bDMARD or JAK inhibitor did not have an obvious influence on circulating adiponectin. CONCLUSIONS: Classification of body composition and multiple regression analysis revealed a positive and independent correlation between serum adiponectin and DAS28-ESR in Japanese RA patients. Thus, serum adiponectin may be an important marker reflecting high disease activity of RA regardless of current medications. Public Library of Science 2020-03-03 /pmc/articles/PMC7053773/ /pubmed/32126127 http://dx.doi.org/10.1371/journal.pone.0229998 Text en © 2020 Minamino et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Minamino, Hiroto
Katsushima, Masao
Yoshida, Tamami
Hashimoto, Motomu
Fujita, Yoshihito
Shirakashi, Mirei
Yamamoto, Wataru
Murakami, Kosaku
Murata, Koichi
Nishitani, Kohei
Tanaka, Masao
Ito, Hiromu
Inagaki, Nobuya
Matsuda, Shuichi
Increased circulating adiponectin is an independent disease activity marker in patients with rheumatoid arthritis: A cross-sectional study using the KURAMA database
title Increased circulating adiponectin is an independent disease activity marker in patients with rheumatoid arthritis: A cross-sectional study using the KURAMA database
title_full Increased circulating adiponectin is an independent disease activity marker in patients with rheumatoid arthritis: A cross-sectional study using the KURAMA database
title_fullStr Increased circulating adiponectin is an independent disease activity marker in patients with rheumatoid arthritis: A cross-sectional study using the KURAMA database
title_full_unstemmed Increased circulating adiponectin is an independent disease activity marker in patients with rheumatoid arthritis: A cross-sectional study using the KURAMA database
title_short Increased circulating adiponectin is an independent disease activity marker in patients with rheumatoid arthritis: A cross-sectional study using the KURAMA database
title_sort increased circulating adiponectin is an independent disease activity marker in patients with rheumatoid arthritis: a cross-sectional study using the kurama database
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7053773/
https://www.ncbi.nlm.nih.gov/pubmed/32126127
http://dx.doi.org/10.1371/journal.pone.0229998
work_keys_str_mv AT minaminohiroto increasedcirculatingadiponectinisanindependentdiseaseactivitymarkerinpatientswithrheumatoidarthritisacrosssectionalstudyusingthekuramadatabase
AT katsushimamasao increasedcirculatingadiponectinisanindependentdiseaseactivitymarkerinpatientswithrheumatoidarthritisacrosssectionalstudyusingthekuramadatabase
AT yoshidatamami increasedcirculatingadiponectinisanindependentdiseaseactivitymarkerinpatientswithrheumatoidarthritisacrosssectionalstudyusingthekuramadatabase
AT hashimotomotomu increasedcirculatingadiponectinisanindependentdiseaseactivitymarkerinpatientswithrheumatoidarthritisacrosssectionalstudyusingthekuramadatabase
AT fujitayoshihito increasedcirculatingadiponectinisanindependentdiseaseactivitymarkerinpatientswithrheumatoidarthritisacrosssectionalstudyusingthekuramadatabase
AT shirakashimirei increasedcirculatingadiponectinisanindependentdiseaseactivitymarkerinpatientswithrheumatoidarthritisacrosssectionalstudyusingthekuramadatabase
AT yamamotowataru increasedcirculatingadiponectinisanindependentdiseaseactivitymarkerinpatientswithrheumatoidarthritisacrosssectionalstudyusingthekuramadatabase
AT murakamikosaku increasedcirculatingadiponectinisanindependentdiseaseactivitymarkerinpatientswithrheumatoidarthritisacrosssectionalstudyusingthekuramadatabase
AT muratakoichi increasedcirculatingadiponectinisanindependentdiseaseactivitymarkerinpatientswithrheumatoidarthritisacrosssectionalstudyusingthekuramadatabase
AT nishitanikohei increasedcirculatingadiponectinisanindependentdiseaseactivitymarkerinpatientswithrheumatoidarthritisacrosssectionalstudyusingthekuramadatabase
AT tanakamasao increasedcirculatingadiponectinisanindependentdiseaseactivitymarkerinpatientswithrheumatoidarthritisacrosssectionalstudyusingthekuramadatabase
AT itohiromu increasedcirculatingadiponectinisanindependentdiseaseactivitymarkerinpatientswithrheumatoidarthritisacrosssectionalstudyusingthekuramadatabase
AT inagakinobuya increasedcirculatingadiponectinisanindependentdiseaseactivitymarkerinpatientswithrheumatoidarthritisacrosssectionalstudyusingthekuramadatabase
AT matsudashuichi increasedcirculatingadiponectinisanindependentdiseaseactivitymarkerinpatientswithrheumatoidarthritisacrosssectionalstudyusingthekuramadatabase